10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-CHRM1 Antibody

Catalog # AP60251

Product Information

Application	WB, IF/IC
Primary Accession	P11229
Reactivity	Human, Mouse, Rat, Mk
Host	Rabbit
Clonality	Polyclonal
Calculated MW	51421

Additional Information


Gene ID	1128
Other Names	Muscarinic acetylcholine receptor M1
Target/Specificity	KLH-conjugated synthetic peptide encompassing a sequence within the center region of human CHRM1. The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000) IF/IC~~N/A
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information


Name	CHRM1
Function	The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Cellular Location	Cell membrane; Multi-pass membrane protein. Postsynaptic cell membrane; Multi-pass membrane protein

Images

Western blot analysis of CHRM1 expression in HEK293T (A), mouse brain (B), rat brain (C), LOVO (D), MCF7 (E) whole cell lysates. (Predicted band size: 51 kD; Observed



band size: 55 kD)



Immunofluorescent analysis of CHRM1 staining in MDAMB231 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a AF488-conjugated secondary antibody (green) in PBS at room temperature in the dark. Phalloidin - AF594 was used to stain Actin filaments (red). DAPI was used to stain the cell nuclei (blue).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.